mTOR inhibitors have been shown to reduce the incidence of malignancies and possibly cause regression of renal cell carcinoma, skin cancers, and Kaposi's sarcoma in transplant patients [15]. This evidence concerns the gene MTOR and Kaposi's sarcoma.